Slide 1: FY26 Results Presentation
ASX Release ASX:TTX FY26 Results Presentation 20th August 2026 Tetratherix Limited (ASX:TTX) (Tetratherix) is pleased to announce its FY26 financial results presentation. A copy of the CEO letter contained in the Annual Report lodged with ASX on 20 August 2026 is also available on Medium. < ENDS > F
Slide 2: FY26 Results Briefing
Tetratherix For personal use only FY26 Results Briefing Tetratherix Limited 2026
Slide 3: Important Information & Disclaimer
IMPORTANT INFORMATION & DISCLAIMER USE OF THIS DOCUMENT You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and
Slide 4: Who is Tetratherix?
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Who is Tetratherix? For personal use only We are an Australian biomedical technology company, founded in 2015 as an advanced manufacturing and intellectual property-generating entity in the biomaterial and regenerati
Slide 5: TTX Timeline - Years in the Making
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead TTX Timeline - 15 Years in the Making WE ARE HERE The TTX Decade Development Arc For personal use only Our first generation of products are Commercial Launch of the launching into global markets in 2026, TTX Platform
Slide 6: TTX by the numbers
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead TTX by the numbers Active Product Programs MARKET LAUNCH 15 Global R&D Infrastructure Years of deep R&D on the cusp of changing lives around the world 10 For personal use only Bone Regeneration Bone Regeneration 6 Ye
Slide 7: The Tetramatrix Platform Technology
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead The Tetramatrix™ Platform Technology For personal use only Tetratherix Limited 2026
Slide 8: The Evolving Dynamics of Global Healthcare Demand
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead The Evolving Dynamics of Global Healthcare Demand Innovative & Cost-Effective Biomaterials 01. Rising Patient Expectations For personal use only Patients are increasingly expecting higher quality of care with a parti
Slide 9: Tetramatrix Platform Technology
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tetramatrix™ Platform Technology Our Tetramatrix platform is best positioned to address the clinical demands that are central to the evolution For personal use only 01 02 03 04 Tetramatrix Universal Seamlessly Bioste
Slide 10: Tetramatrix Platform Technology
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tetramatrix™ Platform Technology Tetramatrix™ is a synthetic material supplied in a ready-to-use syringe format that fits within the existing clinical workflow rather than changing it. It is manufactured locally, at
Slide 11: Clinical Franchises built on a single platform
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tetramatrix™ Clinical Franchises built on a single platform Bone Regeneration Tissue Healing The Tetramatrix™ platform is applied Bone Regeneration products on the Tissue Healing products on the For personal use only
Slide 12: Tetramatrix Product Portfolio Generation 1
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tetramatrix™ Product Portfolio Generation 1 For personal use only Bone Tissue Tissue Precision Our Generation 1 products are the Regeneration Spacing Healing Medicine first commercial derivatives of the Tetramatrix™
Slide 13: FY26 Results & Highlights
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Results & Highlights For personal use only Tetratherix Limited 2026
Slide 14: FY26 Financial Highlights
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Financial Highlights A capital light model with compounding revenue This business was built lean from the outset, not reshaped into it during FY26. For personal use only Income We don't carry the cost of owning
Slide 15: FY26 Financial Highlights: Cashflow
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Financial Highlights Cashflow: $15.6m (before costs) from May 2026 placement plus $4.2m Superpower Licence Revenue has funded incremental growth over and above the IPO strategic plan For personal use only 1 2 $2
Slide 16: FY26 Operational Highlights
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights Patient impact is how we 01 measure our success. Tetramatrix™ platform 04 Federal Government support for Australian Export. With the support of a $3.3m IGP grant, we have now For personal
Slide 17: Growth in Patient Impact
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 01 For personal use only 58% Growth in Patient Impact Patient impact is how we measure our success. The Tetramatrix™ platform has now been used across multiple clinical trials, with more t
Slide 18: Tutelix First In Human Success
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead A. Tutelix First In Human Success The first in human (FIH) clinical trial for Tutelix product was initiated and all planned 15 patients completed their treatment For personal use only with no product related adverse
Slide 19: Tutelix First In Human Success
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead A. Tutelix First In Human Success Product displayed an outstanding structural stability at the injection site for 3 months. MRI results displayed “water intake” at this time point which is a prerequisite for over tim
Slide 20: TetraDerm Clinical Trial Progress
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead B. TetraDerm Clinical Trial Progress TetraDerm Clinical Trial progressed in two sites in Australia. The Operation 1 Week 6 Weeks results from the unblinded cohort 1 showed strong indications of efficacy for the techn
Slide 21: First Revenues of $4.2m
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 02 For personal use only First Revenues of $4.2m* Reaching the commercial inflection point. Tetratherix is now $4.2m in revenues a revenue-generating business, having made the transition f
Slide 22: Completed First FDA Submissions
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 03 For personal use only Completed First FDA Submissions A significant regulatory milestone met. In 2026 Tetratherix completed its first full FDA dossiers, covering the performance and saf
Slide 23: FDA Submission Data Read out
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FDA submission Data Read out As a novel platform material, and to enable effective and efficient 35 motion of our flywheel for our current and future FDA For personal use only submissions, we went above and beyond to
Slide 24: FDA Submission Data Read out
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FDA submission Data Read out Tegenix site Control site The sites were integrated with the host tissue, and the Tegenix treated sites demonstrated For personal use only the product’s proposition, allowing bone ingrowt
Slide 25: FDA Submission Data Read out
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FDA submission Data Read out The results from these clinically relevant models confirmed that Tegenix: (a) acts as an effective carrier for any type of For personal use only bone grafts (animal or human-derived) to e
Slide 26: FDA Submission Data Read out
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FDA submission Data Read out TegenEOS allows effective delivery of TegenEOS autografts to the site for effective For personal use only integration of the newly formed bone with the host environment (turquoise blue ar
Slide 27: Production Readiness Underway
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 04 For personal use only Production Readiness Underway Federal Government support for Australian export. With the backing of a $3.3m Industry Growth Program grant, we have begun building a
Slide 28: Precision Medicine Launch
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 05 For personal use only Precision Medicine Launch New franchise launched in the fast growing drug Changing the way drugs are delivered, on the back of more delivery market than five years
Slide 29: Paving the Path with our Pipeline
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead FY26 Operational Highlights 06 For personal use only The Tetramatrix™ Paving the Path with our Pipeline platform continues to grow Growing patient impact, anchored by science. Working closely with our development par
Slide 30: FY26 - A year of relentless execution of the TTX Mission
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Directional Momentum FY26 - A year of relentless execution of the TTX Mission Henry Schein Supply & Data read-out FDA Submission Licensing Agreement from the pre- Completion 3 Execution clinical study Tegenix For per
Slide 31: The Opportunity Ahead
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead For personal use only The Opportunity Ahead Tetratherix Limited 2026
Slide 32: Tetramatrix Product Portfolio Generation 1
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tetramatrix™ Product Portfolio Generation 1 For personal use only Bone Tissue Tissue Precision Our Generation 1 products are the Regeneration Spacing Healing Medicine first commercial derivatives of the Tetramatrix™
Slide 33: Product Segmentation - Generation 1
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Product Segmentation - Fast Generation 1 Tegenix For personal use only TegenEOS Bone Bone Regeneration STEPP TegenEOS Longevity Multiple Biologics Precision Medicine Time to Revenue Prostate Compounding Tutelix STEPP
Slide 34: Bone Regeneration
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead For personal use only Bone Regeneration Tetratherix Limited 2026
Slide 35: Product Segmentation: Bone Regeneration
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead First application to market Product Segmentation Rapid Displacement via venture partnership Bone Regeneration - Generation 1 Scaled Disruption with commercial partner Size of bubble reflects TAM Opportunity Tegenix a
Slide 36: Tissue Spacing
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead For personal use only Tissue Spacing Tetratherix Limited 2026
Slide 37: Product Segmentation: Tissue Spacing
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead First application to market Product Segmentation Rapid Displacement via venture partnership Tissue Spacing - Generation 1 Scaled Disruption with commercial partner Size of bubble reflects TAM Opportunity Tutelix is t
Slide 38: Tissue Healing
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Tissue Healing For personal use only Tetratherix Limited 2026
Slide 39: Product Segmentation: Tissue Healing
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead First application to market Product Segmentation Rapid Displacement via venture partnership Tissue Healing - Generation 1 Scaled Disruption with commercial partner Size of bubble reflects TAM Opportunity TetraDerm is
Slide 40: Precision Medicine
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead For personal use only Precision Medicine Tetratherix Limited 2026
Slide 41: Product Segmentation: Precision Medicine
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead First application to market Product Segmentation Rapid Displacement via venture partnership Precision Medicine - Generation 1 Scaled Disruption with commercial partner Size of bubble reflects TAM Opportunity STEPP is
Slide 42: FY27 - The year TTX transitions to commercialisation
Company Overview Platform Overview FY26 Results & Highlights FY27 Opportunity Ahead Directional Momentum FY27 - The year TTX transitions to commercialisation FDA First Final Product US Market Jurisdictional Clearance Dispatch to HS Seeding Market Expansion Tegenix For personal use only FDA Supply an
Slide 43: For personal use only
For personal use only Tetratherix Limited 2026 ASX: TTX